x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

Asia ( XML Feed )

Jul 7, 2016 11:38 EST

Vernx Biotechnology aims to be the global leader in commercialising nutritional products aimed at reducing necrotising enterocolitis and other gut disorders in premature infants.

iCrowdNewswire - Jul 7, 2016

Vernx 20pink 20and 20black 20small 20for 20linkin

 

 

Vernx Biotechnology

 

 

Helping premature infants thrive.

 

 

 

Istock 000083194021 large

 

 

Company Summary

 

Vernx Biotechnology aims to be the global leader in commercialising nutritional products aimed at reducing necrotising enterocolitis and other gut disorders in premature infants. Vernx will be the first company in the APAC region to sell human donor milk and human milk fortifier to hospitals. In addition we will commercialise a novel fatty acid to help improve gut disease in premature infants. Vernx is owned by the two founders.

 

 

 

  • StageFull Product Ready
  • IndustryBiotechnology
  • LocationWollongong, New South Wales, Australia
  • CurrencyAUD
  • FoundedFebruary 2016
  • Employees2
  • Incorporation TypeNot Incorporated
  • Websitevernx.com

 

 

 

 

Team

  • 8aeb5e35 4b92 4c59 96c3 6b160e3b9885
    Co-Founder, CEO

    Biotechnology innovator with over 20 years experience. Chief innovation officer at Clover Corporation. Leader in the spin out of IP related to premature infant nutrition. Founding Director of commercial development at Premneo pharmaceuticals. Craig is also Co-Founder and Director of a social enterprise, Feedback Nutrition.

     

     

     

  • 1f51d125 8a60 4458 8093 4eb16a86fe0e
    Co-Founder, Director, R&D

    10 years of product development experience with Clover Corporation. Co-inventor of Premneo DHA oral solution used in largest premature infant trial in collaboration with Women’s and Children’s hospital Adelaide. She is also Co-Founder and Director of a social enterprise, Feedback Nutrition.

 

 

 

 

 

 

Contact Information:

Craig Patch

View Related News >
support